Re: Johansson E, Giovannitti M, Mezzetti M, et al. Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective. J Med Econ. 2023;26(1):1155-1166

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of medical economics 2024-01, Vol.27 (1), p.800-802
Hauptverfasser:	Pedone, Maria Paola, Dobreva, Miryana, Bastian, Mike, Tavi, Jules, Noonan, Kerry
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - economics Antibodies, Monoclonal, Humanized - therapeutic use Azetidines - economics Azetidines - therapeutic use Cost-Benefit Analysis Cost-Effectiveness Analysis Dermatitis, Atopic - drug therapy Dermatitis, Atopic - economics Humans Italy Purines - economics Purines - therapeutic use Pyrazoles - economics Pyrazoles - therapeutic use Severity of Illness Index Sulfonamides - economics Sulfonamides - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!